|

ML261 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • Moonlight Bio, Inc1

Indications

  • Neuroendocrine Prostate Cancer (NEPC)1
  • Gastroenteropancreatic NEC (GEP NEC)1
  • Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)1
  • Small Cell Lung Cancer (SCLC)1
  • Lung Cancer1

St Louis, Missouri1 trial

A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)

Washington University Medicine

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.